LON:ERGO Ergomed (ERGO) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ergomed Stock (LON:ERGO) 30 days 90 days 365 days Advanced Chart Get Ergomed alerts:Sign Up Key Stats Today's Range N/A50-Day Range 1,346▼ 1,34652-Week Range N/AVolume280,999 shsAverage Volume346,578 shsMarket Capitalization£701.00 millionP/E Ratio4,641.38Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewErgomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.Read More… Receive ERGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter. Email Address ERGO Stock News HeadlinesAktuelle Empfehlungen zur ERGOMEDJanuary 20, 2025 | finanznachrichten.deErgomedcro Unveils New Pune Office, Reinforcing Commitment to Global GrowthOctober 12, 2024 | markets.businessinsider.com‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.April 18, 2025 | Stansberry Research (Ad)Icon PLC IJFFebruary 6, 2024 | morningstar.comGreen Mining Innovation: Neuer Chief Financing OfficerJanuary 14, 2024 | finanznachrichten.deGreen Mining Innovation: New Chief Financing OfficerJanuary 13, 2024 | finanznachrichten.dePermira Hires Maschmeyer From Vistria for Health-Care InvestingJanuary 4, 2024 | msn.com3 high-growth penny stocks to consider buying for 2024December 31, 2023 | msn.comSee More Headlines ERGO Stock Analysis - Frequently Asked Questions How were Ergomed's earnings last quarter? Ergomed plc (LON:ERGO) issued its quarterly earnings data on Monday, September, 18th. The company reported $1.20 earnings per share (EPS) for the quarter. The firm earned $22.91 million during the quarter. Ergomed had a net margin of 9.87% and a trailing twelve-month return on equity of 18.08%. How do I buy shares of Ergomed? Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Ergomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), FuelCell Energy (FCEL), Frontier Developments (FDEV), Future (FUTR), Lloyds Banking Group (LLOY) and NIO (NIO). Company Calendar Last Earnings9/18/2017Today4/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolLON:ERGO CIKN/A Webwww.ergomedplc.com Phone+44-1483-503205FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.29 Trailing P/E Ratio4,641.38 Forward P/E RatioN/A P/E GrowthN/ANet Income£15 million Net Margins9.87% Pretax MarginN/A Return on Equity18.08% Return on Assets10.16% Debt Debt-to-Equity Ratio3.32 Current Ratio1.79 Quick Ratio1.22 Sales & Book Value Annual Sales£152.09 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow54.67 Book ValueGBX 179 per share Price / BookN/AMiscellaneous Outstanding Shares52,080,000Free FloatN/AMarket Cap£701.00 million OptionableNot Optionable Beta0.79 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:ERGO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ergomed plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ergomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.